216 related articles for article (PubMed ID: 24445502)
1. Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.
Eisen T; Hedlund G; Forsberg G; Hawkins R
Curr Oncol Rep; 2014 Feb; 16(2):370. PubMed ID: 24445502
[TBL] [Abstract][Full Text] [Related]
2. Naptumomab estafenatox: a new immunoconjugate.
Robinson MK; Alpaugh RK; Borghaei H
Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
[TBL] [Abstract][Full Text] [Related]
3. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
[TBL] [Abstract][Full Text] [Related]
4. The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.
Hedlund G; Eriksson H; Sundstedt A; Forsberg G; Jakobsen BK; Pumphrey N; Rödström K; Lindkvist-Petersson K; Björk P
PLoS One; 2013; 8(10):e79082. PubMed ID: 24194959
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
[TBL] [Abstract][Full Text] [Related]
6. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.
Elkord E; Burt DJ; Sundstedt A; Nordle Ö; Hedlund G; Hawkins RE
Oncotarget; 2015 Feb; 6(6):4428-39. PubMed ID: 25669986
[TBL] [Abstract][Full Text] [Related]
7. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9791-5. PubMed ID: 7568219
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis.
Hawkins RE; Gore M; Shparyk Y; Bondar V; Gladkov O; Ganev T; Harza M; Polenkov S; Bondarenko I; Karlov P; Karyakin O; Khasanov R; Hedlund G; Forsberg G; Nordle Ö; Eisen T
Clin Cancer Res; 2016 Jul; 22(13):3172-81. PubMed ID: 26851187
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
10. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
[TBL] [Abstract][Full Text] [Related]
11. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U
Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049
[TBL] [Abstract][Full Text] [Related]
12. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
13. Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.
Patterson KG; Dixon Pittaro JL; Bastedo PS; Hess DA; Haeryfar SM; McCormick JK
PLoS One; 2014; 9(4):e95200. PubMed ID: 24736661
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies and superantigens: a novel therapeutic approach.
Kalland T; Dohlsten M; Lind P; Sundstedt A; Abrahmsén L; Hedlund G; Björk P; Lando PA; Björklund M
Med Oncol Tumor Pharmacother; 1993; 10(1-2):37-47. PubMed ID: 8258993
[TBL] [Abstract][Full Text] [Related]
15. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
Borghaei H; Alpaugh K; Hedlund G; Forsberg G; Langer C; Rogatko A; Hawkins R; Dueland S; Lassen U; Cohen RB
J Clin Oncol; 2009 Sep; 27(25):4116-23. PubMed ID: 19636016
[TBL] [Abstract][Full Text] [Related]
17. Construction and characterization of a novel superantigen fusion protein: bFGF/SEB.
Wang L; Zhang H; Zhang S; Yu M; Yang X
Cancer Invest; 2009 May; 27(4):376-83. PubMed ID: 19160106
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of human colon cancer by antibody-targeted superantigens.
Dohlsten M; Lando PA; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T
Cancer Immunol Immunother; 1995 Sep; 41(3):162-8. PubMed ID: 7553685
[TBL] [Abstract][Full Text] [Related]
19. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.
Rosendahl A; Kristensson K; Hansson J; Ohlsson L; Kalland T; Dohlsten M
Int J Cancer; 1998 Apr; 76(2):274-83. PubMed ID: 9537591
[TBL] [Abstract][Full Text] [Related]
20. Immune response during tumor therapy with antibody-superantigen fusion proteins.
Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
